An exploratory study of the acceptability, and impact on health-related quality of life of long-acting cabotegravir + rilpivirine in people with HIV and cognitive impairment

niversity of Sussex0 sites20 target enrollmentJanuary 19, 2024

Overview

No summary available.

Registry

who.int

Start Date

January 19, 2024

End Date

July 14, 2026

Last Updated

2 years ago

Study Type

Observational

Sex

All

Sponsor

niversity of Sussex

•1\. Eligible for LA injectable ART by the multidisciplinary (MDT) clinical team at University Hospitals Sussex NHS Foundation Trust based on criteria defined by the British HIV Association (BHIVA)
•2\. HIV\-1 positive subjects
•3\. Age \= 40 years old
•4\. Evidence of clinically significant cognitive impairment, which for this protocol will be defined as participants meeting all of the following criteria:
•4\.1\. Patient\-reported symptoms of cognitive impairment (ongoing symptoms)
•4\.2\. Current or past clinical neuropsychological testing reporting cognitive impairment
•5\. Able to understand the study, sign the consent form, and be willing to undertake all study procedures

•1\. Patient deemed not to be eligible for LA injectable CAB\+RPV by the MDT clinical team and based on the criteria defined by BHIVA
•2\. Existing neurological disease that could affect the ability of patients to participate in the study
•3\. Current history of major depression or psychosis
•4\. Recent head injury (past six months)
•5\. Current alcohol abuse or drug dependence
•6\. Has completed the CogniFit assessment in the last year for clinical or research purposes